Leerink Partners Raises Henry Schein (NASDAQ:HSIC) Price Target to $87.00

Henry Schein (NASDAQ:HSIC) had its price target upped by equities research analysts at Leerink Partners from $75.00 to $87.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “market perform” rating on the stock. Leerink Partners’ price objective points to a potential upside of 3.97% from the stock’s current price.

A number of other equities analysts have also issued reports on the stock. Barclays initiated coverage on shares of Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 target price on the stock. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Barrington Research set a $79.00 target price on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Finally, Robert W. Baird set a $100.00 price target on Henry Schein and gave the company an “outperform” rating in a report on Monday. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and a consensus price target of $79.75.

Henry Schein Stock Performance

Henry Schein stock traded up $3.11 during trading hours on Tuesday, reaching $83.68. 3,257,494 shares of the company were exchanged, compared to its average volume of 1,353,549. Henry Schein has a 12 month low of $60.56 and a 12 month high of $89.29. The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The stock has a 50-day moving average of $77.43 and a 200 day moving average of $71.78. The firm has a market cap of $9.85 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 2.37 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.04. The business had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts anticipate that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HSIC. Westwood Holdings Group Inc. bought a new position in Henry Schein in the 2nd quarter worth approximately $20,631,000. AlphaQuest LLC boosted its position in Henry Schein by 91.8% in the 3rd quarter. AlphaQuest LLC now owns 20,861 shares of the company’s stock valued at $1,385,000 after buying an additional 9,987 shares during the last quarter. Berger Financial Group Inc acquired a new stake in shares of Henry Schein in the 3rd quarter valued at $2,981,000. SVB Wealth LLC acquired a new stake in shares of Henry Schein in the 2nd quarter valued at $1,415,000. Finally, Brandywine Global Investment Management LLC raised its position in shares of Henry Schein by 5.4% during the second quarter. Brandywine Global Investment Management LLC now owns 79,102 shares of the company’s stock worth $5,778,000 after acquiring an additional 4,061 shares during the last quarter. 96.62% of the stock is owned by institutional investors.

Trending Headlines about Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 beat — Henry Schein reported EPS of $1.34 vs. consensus $1.30 and revenue of $3.44B vs. $3.34B, with revenue up ~7.7% year-over-year. The outperformance on top- and bottom-line results is the primary driver behind the rally. Reuters: Henry Schein beats quarterly profit estimates
• Positive Sentiment: FY‑2026 guidance steady/slightly positive — Management set EPS guidance of $5.230–$5.370 and revenue guidance of $13.6B–$13.8B (above the $13.5B consensus), signaling stabilized demand in dental/medical equipment and supporting forward expectations. Benzinga: Henry Schein Stock Hits 52-Week High
• Positive Sentiment: Analyst upgrade — Robert W. Baird upgraded HSIC from Neutral to Outperform and raised the price target to $100, providing additional buy-side endorsement and momentum. MSN: Baird upgrades Henry Schein
• Neutral Sentiment: Investor materials available — Management released the press deck and hosted the earnings call; investors can review slides and the call for segment-level details and cadence into FY‑2026. Press Release / Slide Deck
• Negative Sentiment: Margin pressure — While revenue and EPS beat, gross/profit margin contraction was noted in commentary and coverage, which tempers the beat and could limit multiple expansion if margins don’t recover. Zacks: HSIC Q4 — Revenues beat, margins down

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.